Clinical Trials
3 trialsNCT04285086 2025-08-13
SURPASS ET
PharmaEssentia
Phase 3 Active not recruiting
NCT03123588 2021-11-19
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
Phase 2 Terminated
NCT02076815 2015-07-29
TEAM-ET
AOP Orphan Pharmaceuticals AG
Phase 3 Completed